pharmaphorum3d
Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition
Sanofi is to buy Principia Biopharma for up to $3.68 billion ... give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty ...
pharmaphorum1d
FDA slaps partial hold on Biogen, InnoCare MS drug
Liver injuries also prompted the FDA to impose a partial clinical hold on Sanofi's BTK inhibitor tolebrutinib (SAR442168 ... of its $3.7 billion buyout of Principia Biopharma.
appliedclinicaltrialsonline3d
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) (HERCULES). ClinicalTrials.gov. Updated February 3, ...